Display options
Cite
Dosch J, Ziemke E, Wan S, et al. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget. 2017;8(39):65090-65099doi: 10.18632/oncotarget.17780.
Dosch, J., Ziemke, E., Wan, S., Luker, K., Welling, T., Hardiman, K., Fearon, E., Thomas, S., Flynn, M., Rios-Doria, J., Hollingsworth, R., Herbst, R., Hurt, E., & Sebolt-Leopold, J. (2017). Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget, 8(39), 65090-65099. https://doi.org/10.18632/oncotarget.17780
Dosch, Joseph, et al. "Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency." Oncotarget vol. 8,39 (2017): 65090-65099. doi: https://doi.org/10.18632/oncotarget.17780
Dosch J, Ziemke E, Wan S, Luker K, Welling T, Hardiman K, Fearon E, Thomas S, Flynn M, Rios-Doria J, Hollingsworth R, Herbst R, Hurt E, Sebolt-Leopold J. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget. 2017 May 10;8(39):65090-65099. doi: 10.18632/oncotarget.17780. eCollection 2017 Sep 12. PMID: 29029414; PMCID: PMC5630314.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 May 10;8(39):65090-65099. doi: 10.18632/oncotarget.17780. eCollection 2017 Sep 12.

Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.

Oncotarget

Joseph Dosch, Elizabeth Ziemke, Shanshan Wan, Kathryn Luker, Theodore Welling, Karin Hardiman, Eric Fearon, Suneetha Thomas, Matthew Flynn, Jonathan Rios-Doria, Robert Hollingsworth, Ronald Herbst, Elaine Hurt, Judith Sebolt-Leopold

Affiliations

  1. Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA.
  2. Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
  3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
  4. Department of Oncology Research, MedImmune, LLC, Gaithersburg, MD 20878, USA.

PMID: 29029414 PMCID: PMC5630314 DOI: 10.18632/oncotarget.17780

Abstract

ADAM17 (a disintegrin and metalloproteinase 17)/TACE (TNFα converting enzyme) has emerged as a potential therapeutic target in colorectal cancer (CRC) and other cancers, due in part to its role in regulating various tumor cell surface proteins and growth factors and cytokines in the tumor microenvironment. The emergence of MEDI3622, a highly potent and specific antibody-based ADAM17 inhibitor, has allowed testing of the concept that targeting ADAM17 may be an important new therapeutic approach for CRC patients. We demonstrate that MEDI3622 is highly efficacious on tumor growth in multiple human CRC PDX models, resulting in improved survival of animals bearing tumor xenografts. MEDI3622 was further found to impact Notch pathway activity and tumor-initiating cells. The promising preclinical activity seen here supports further clinical investigation of this treatment approach to improve therapeutic outcome for patients diagnosed with metastatic CRC, including patients with KRAS-mutant tumors for whom other therapeutic options are currently limited.

Keywords: ADAM17; Notch; TACE; colorectal; stem cell

Conflict of interest statement

CONFLICTS OF INTEREST Suneetha B. Thomas, Matthew Flynn, Jonathan Rios-Doria, Robert E. Hollingsworth, and Elaine M. Hurt are employees of MedImmune, LLC and hold AstraZeneca shares. Judith S. Sebolt-

References

  1. Nat Rev Cancer. 2008 Dec;8(12 ):929-41 - PubMed
  2. Cancer Discov. 2015 Feb;5(2):115-7 - PubMed
  3. J Pathol. 2005 Oct;207 (2):156-63 - PubMed
  4. PLoS One. 2015 Jul 15;10 (7):e0132661 - PubMed
  5. Mol Cancer Ther. 2015 Jul;14 (7):1637-49 - PubMed
  6. Cancer Discov. 2015 Feb;5(2):198-211 - PubMed
  7. Mol Carcinog. 2012 Feb;51(2):150-64 - PubMed
  8. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6 - PubMed
  9. Carcinogenesis. 2013 Oct;34(10):2415-23 - PubMed
  10. Cancer Cell. 2013 Feb 11;23 (2):171-85 - PubMed
  11. Clin Cancer Res. 2008 Feb 15;14 (4):1182-91 - PubMed
  12. J Cell Biol. 1992 Aug;118(3):741-51 - PubMed
  13. Cancer Res. 2013 May 15;73(10):2955-64 - PubMed
  14. Cancer Res. 1992 Jun 15;52(12):3467-73 - PubMed
  15. Carcinogenesis. 2009 Dec;30(12):1979-86 - PubMed
  16. Clin Cancer Res. 2010 Jul 1;16(13):3378-89 - PubMed
  17. N Engl J Med. 2000 Sep 28;343 (13):905-14 - PubMed
  18. PLoS One. 2012;7(12 ):e50791 - PubMed
  19. Biochem Biophys Res Commun. 2009 Feb 27;380(1):33-8 - PubMed
  20. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed

Publication Types

Grant support